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HLA-B*57 is the class I allele most strongly as-
sociated with control of HIV-1 infection (1–3).   
Because  CTLs  recognize  viral  peptides  pre-
sented by HLA class I molecules on the sur-
face of infected cells, this clear relationship 
between HLA-B*57 and lower viral loads may 
be a result of the specific HIV peptides that 
are displayed by this allele and the potent CTL 
responses targeting these peptides. It is hypoth-
esized that the CTL responses appearing early 
in infection are those that most strongly influ-
ence clinical outcome (4), and HLA-B*57–re-
stricted CTL responses have been shown to 
dominate in early HIV infection in individu-
als with this HLA allele (5). In SIV, Gag-de-
rived CTL epitopes are presented early in the 
infection cycle of a cell (6), and HLA-B*5703 
presents three epitopes in the capsid region 
of HIV-1 Gag p24: ISW9 (ISPRTLNAW; 
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HLA-B*57 is the class I allele most consistently associated with control of human immuno-
deficiency virus (HIV) replication, which may be linked to the specific HIV peptides that this 
allele presents to cytotoxic T lymphocytes (CTLs), and the resulting efficacy of these cellu-
lar immune responses. In two HIV C clade–infected populations in South Africa and Zambia, 
we sought to elucidate the role of HLA-B*5703 in HIV disease outcome. HLA-B*5703–
restricted CTL responses select for escape mutations in three Gag p24 epitopes, in a pre-
dictable order. We show that the accumulation of these mutations sequentially reduces 
viral replicative capacity in vitro. Despite this, in vivo data demonstrate that there is ulti-
mately an increase in viral load concomitant with evasion of all three HLA-B*5703–re-
stricted CTL responses. In HLA-B*5703–mismatched recipients, the previously described 
early benefit of transmitted HLA-B*5703–associated escape mutations is abrogated by the 
increase in viral load coincident with reversion. Rapid disease progression is observed in 
HLA-matched recipients to whom mutated virus is transmitted. These data demonstrate 
that, although costly escape from CTL responses can progressively attenuate the virus, high 
viral loads develop in the absence of adequate, continued CTL responses. These data under-
line the need for a CTL vaccine against multiple conserved epitopes.
© 2009 Crawford et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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negative population in Zambia is likely related to the higher 
prevalence  of  HLA-B*5703  in  Lusaka,  Zambia  compared 
with KwaZulu-Natal, South Africa (16). Sequences from all 
HLA-B*5703–positive individuals in both cohorts contained 
at least one of these mutations (Fig. 1 C), and we inferred an 
Gag 147–155), KF11 (KAFSPEVIPMF; Gag 162–172), and 
TW10 (TSTLQEQIAW; Gag 240–249).
In addition to the presentation of multiple Gag epitopes 
(7), the association of HLA-B*5703 with low viremia is re-
lated to the selection of multiple escape mutations within 
these epitopes (8). These HLA-B*5703–associated mutations 
reduce viral replicative capacity, as shown either from in vivo 
reversion to consensus after their transmission to HLA-B*57–
negative individuals (8–11) or from in vitro viral growth as-
says (10, 12, 13). However, despite the decrease in replicative 
capacity conferred by these mutations, individuals with HLA-
B*5703 eventually progress to disease, albeit at a slow rate 
(14). The cause for the loss of control of virus replication and 
the concomitant increase in viral load remains unclear.
The influence on disease course of mutations selected in 
an HLA-B*5703 environment can be followed after trans-
mission to HLA-mismatched recipients. Two studies exam-
ining HLA-B*5703–negative recipients, followed for up to   
1 yr after transmission, have shown an advantage to being in-
fected by a virus with two or more HLA-B*5703–associated 
mutations, which resulted in lower viral set points (9, 15). 
However, the long-term effects of infection by low fitness 
escape mutants have not been examined.
We studied two independent HIV-1 C clade–infected 
cohorts in Southern Africa, where HLA-B*5703 is the pre-
dominant HLA-B*57 allele, with two aims: first, to define 
more clearly the role of HLA-B*5703 in both control of 
  virus replication and disease progression in HLA-B*5703–
positive subjects; and second, to examine the long-term 
impact of HLA-B*5703 after transmission of a virus con-
taining HLA-B*5703–associated mutations to HLA-matched 
and -mismatched individuals.
RESULTS
Predictable appearance of HLA-B*5703–associated escape 
mutations in distinct Southern African cohorts
Previous studies in Durban, South Africa have shown that 
early HIV-1 infection in HLA-B*5703–positive individuals is 
characterized by the selection of mutations in two Gag p24 
epitopes, ISW9 (ISPRTLNAW; Gag 147–155) and TW10 
(TSTLQEQIAW; Gag 240–249), followed by those in KF11 
(KAFSPEVIPMF; Gag 162–172) (10). To characterize viral 
sequence changes occurring over time in Zambian transmis-
sion pairs where either the donor or the recipient expressed 
HLA-B*5703, we first undertook a cross-sectional analysis of 
viral p24 amino acid sequences generated from 178 HIV-in-
fected (including 42 HLA-B*5703–positive) individuals in 
Lusaka, Zambia. For the purposes of these studies, the Zam-
bian subjects studied included a high proportion of individu-
als expressing HLA-B*5703. The results are consistent with 
those observed in the study population of 645 HIV-infected 
individuals in Durban, South Africa (Fig. 1, A and B), with 
mutations in the three associated epitopes exhibiting compa-
rable frequencies in the HLA-B*5703–positive populations 
in the two cohorts. The reason for the somewhat higher fre-
quencies of A146X and I147X observed in the HLA-B*5703–
Figure 1.  HLA-B*5703–associated polymorphisms in Gag p24 in 
two independent cohorts. (A and B) Association of polymorphisms 
within three B*5703-restricted epitopes (ISW9, KF11, and TW10), and the 
expression of HLA-B*5703 in (A) a South African cohort and (B) a Zambian 
cohort. All associations were statistically significant (P < 0.0001 [P = 0.005 
for I247X in Zambia] using Fisher’s exact test). Individuals expressing HLA-
B*5801 were excluded from this analysis, as this allele also selects for 
escape mutations at residues 146, 147, and 242. (C) Sequence polymor-
phisms in three p24 HLA-B*5703–restricted epitopes, inferring the order 
of accumulation, and similar frequencies of these variants in the two co-
horts. X represents a change away from HIV-1 C clade consensus.JEM VOL. 206, April 13, 2009 
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p24 CTL responses arise despite the considerable fitness costs 
associated with such changes shown from in vitro assays. This 
fits with data showing that the presence of a KF11 CTL re-
sponse is associated with a 10-fold lower viral load in HLA-
B*5703–positive individuals (7). Collectively, these findings 
confirm that the advantage to the virus conferred by escaping 
these CTL responses (the KF11 CTL response in particular) 
far outweighs the replication costs of the mutations. Other 
factors that may play a role in the higher viral loads are the 
length of time of infection and the prior selection of HLA-
B*5703–associated compensatory mutations in ±20% of 
individuals, although no known compensatory mutations de-
veloped in these individuals during the time studied.
Early escape in HLA-B*5703–positive individuals
To better understand the relationship of HLA-B*5703 “foot-
print” mutations with in vivo viral replication, we tracked vi-
ral  sequence  changes  in  Gag  p24  in  five  acutely  infected 
HLA-B*5703–positive individuals from Zambia for a median 
time of 17 mo (range = 11–58 mo), and correlated the changes 
with variations in viral load. Because individuals in this co-
hort are sampled every 3 mo, the first time point is within   
3 mo of transmission, and often the initial peak in viral load is 
missed. The presence of early CTL responses targeting the 
HLA-B*5703 epitopes ISW9 and TW10 was suggested by 
the relatively low median viral load of 10,309 copies/ml even 
at the first time point after seroconversion, and by the selec-
tion of CTL escape mutations (Fig. 3, A–E). Escape in was 
first detected at a median time after seroconversion of 13 mo 
(range = 4–18 mo). To determine what effect the escape mu-
tations had on disease course in each individual, we calculated 
the median value of each individual’s viral loads before escape 
was detected and compared this with the median value of the 
viral loads after escape (Fig. 3 F). Although escape mutations 
were being selected in the ISW9 and TW10 epitopes, there 
was no increase in viral load akin to that seen after the appear-
ance of KF11 mutations (Fig. 3, B–D). This is consistent with 
a balance being maintained between the persistent wild type–
specific  immune  response  or  de  novo  variant–specific  re-
sponses, and the reduced replicative capacity of the virus. 
Examining  these  5  HLA-B*5703–positive  individuals  to-
gether over 18 mo of infection (Fig. 3 G), we observed lower 
viral loads compared with the majority of 23 HLA-B*5703–
negative subjects with acute infection (who were sampled 
every 6 mo), whose virus carried no HLA-B*5703 footprints 
(Fig. 3 H). This finding, in addition to the large difference 
between the initial viral loads in the HLA-B*5703–positive and 
–negative subjects (median = 13,000 vs. 43,000 copies/ml), 
is consistent with the known early impact of multiple Gag-
specific CTL responses restricted by HLA-B*5703.
Early benefit of transmitted HLA-B*5703 escape  
mutations is abrogated by reversion  
in HLA-B*5703–negative individuals
Recent studies have found that the transmission of virus con-
taining CTL escape mutations in p24 to HLA-mismatched 
order of appearance from these cross-sectional data: changes 
away from consensus were more common in and around ISW9 
and in TW10 compared with KF11, and those in ISW9 were 
present before those in TW10, followed by KF11 (Fig. 1 C). 
This may be a result of the timing of CTL responses targeting 
these epitopes, or it may suggest that the later mutations are 
more costly to the virus and are therefore delayed. It is of in-
terest to note that the order of appearance of mutations in 
these C-clade HLA-B*5703 African populations differs from 
that reported for a B-clade HLA-B*5701 Caucasian popula-
tion, where escape mutations in TW10 were observed first, 
followed by those in ISW9 and KF11 (17).
HLA-B*5703–restricted p24 CTL responses are vital  
in the control of HIV-1 infection
The reversion of these individual HLA-B*5703–associated 
mutations upon transmission to HLA-mismatched recipients 
signifies the negative impact they have on viral replicative 
capacity (9–11). We sought to determine the impact not sim-
ply of the individual mutations but of the accumulation of 
these mutations on replicative capacity as they arise in vivo. 
Therefore, we introduced mutations sequentially into these 
epitopes in a C-clade recombinant p24 plasmid.
Using site-directed mutagenesis, three mutant viruses were 
constructed (Fig. 2 A): the first incorporated the A146P and 
I147L substitutions at positions 1 and +1 of ISW9; the sec-
ond incorporated the T242N mutation in TW10, in addition 
to A146P/I147L; and the third added the KF11 mutations 
A163G  and  S165N  to  A146P/I147L/T242N.  Jurkat  cells 
were infected in triplicate at a multiplicity of infection of 0.01 
with wild-type virus and the three mutant constructs. Viral 
spread was determined over 8 d by measuring the percentage 
of GFP-positive cells by flow cytometry. There was a signifi-
cant decrease in replication as mutations in each HLA-B*5703 
epitope were introduced, with very low numbers of infected 
cells observed in the virus with the complete spectrum of mu-
tations (<1% of wild-type levels). Although we previously 
showed  that  S165N  acts  as  a  compensatory  mutation  for 
A163G in KF11 (10), its presence here cannot compensate for 
the loss of fitness imposed by mutations in all three epitopes. 
Thus, in natural infection, HLA-B*5703 CTL responses se-
lect for Gag mutations that progressively attenuate the virus.
To assess the impact of these escape mutations on control of 
viremia in HLA-B*5703–positive subjects, we compared viral 
loads in 42 chronically infected Zambian subjects (Fig. 2 B).   
In contrast to viral loads in individuals who had mutations in 
ISW9 alone or ISW9 and TW10, significantly higher viral 
loads were observed in those individuals with mutations in   
all three p24 epitopes (P = 0.02 using the Mann-Whitney   
U test). Data from two chronically infected HLA-B*5703–
positive individuals studied, which were the only subjects in 
whom a mutation in KF11 arose during longitudinal follow 
up, also suggest that the selection of A163X in KF11 in sub-
jects with a declining viremia may precipitate a higher final 
viral load (Fig. 2, C and D). Thus, the higher viral loads asso-
ciated  with  escape  from  all  three  HLA-B*5703–restricted 912 EVOLUTION OF HLA-B*5703 HIV-1 ESCAPE MUTATIONS | Crawford et al.
HLA-B*5703  p24  epitopes  was  the  reversion  of  N242T, 
which was complete by time point five (7 wk later), after 
which the individual received antiretroviral treatment (this 
polymorphism was also the only change occurring in p24). A 
comparison of the median value of all viral loads for each in-
dividual before reversion with the median value of all viral 
loads after reversion showed an increase in seven out of nine 
individuals (Fig. 4 D; P = 0.07 using the Wilcoxon matched 
pairs test). In all cases, reversion of T242N in TW10 was ob-
served. Additionally, A146P and/or I147L reverted in three 
cases. These reversions were detected at a median of 23 mo 
after seroconversion (range = 7–55 mo).
The increase in viral load, coincident with reversions, in 
seven out of nine HLA-B*5703–negative recipients (Fig. 4 D) 
contrasts with the decreases in viral load seen in the two 
HLA-B*5703–negative recipients in whom reversion did 
not occur (Fig. 4 A), and with the lack of a consistent trend 
in the control group (Fig. 3 H). In addition, viral loads for 
these nine HLA-B*5703–negative individuals over 18 mo 
(Fig. 4 E) tended to be 10-fold higher than those in the five 
HLA-B*5703–positive individuals (Fig. 3 G) over the same 
period of time (P < 0.0001 using the Mann-Whitney U test) 
and continued to increase. It appears that reversion to a fit-
ter phenotype once infection is established can result in a 
substantial increase in viral load.
individuals resulted in lower viral loads in acute infection (9, 
15), but the long-term effects of transmission of these variants 
on viral load are not known. To examine the longer-term 
consequences of transmission of HLA-B*5703 escape muta-
tions to HLA-B*5703–negative subjects, we identified 11 
Zambian transmission pairs in which the donor was HLA-
B*5703 positive, the recipient was HLA-B*5703 negative, 
and their viruses were epidemiologically linked. Population 
sequencing of viral RNA from both partners at the time of 
transmission revealed that, in all cases, the donor transmitted 
a virus with an HLA-B*5703 footprint (and in six of those 
pairs for which single genome amplicons were sequenced, it 
appears that one virus founded the recipient’s infection). In 
two  recipients,  these  HLA-B*5703  mutations  were  stable 
during the time studied (7 and 20 mo), and their viral loads 
decreased (Fig. 4 A). Transmission of less fit variants, as well 
as early non–HLA-B*5703–restricted CTL responses, may 
have contributed to the decrease observed. In the nine other 
HLA-B*5703–negative recipients, studied for a median time 
of 44 mo (range = 16–62 mo), reversion of HLA-B*5703–
associated mutations occurred (Fig. 4, B and C). In one indi-
vidual (Fig. 4 B), the appearance of wild-type virus at time 
point four, creating a mixed population, was coincident with 
a large increase in viral load, to above the assay limit. Se-
quence data showed that the only change occurring in the 
Figure 2.  In vitro and in vivo effects of cumulative HLA-B*5703 mutations in HLA-B*5703–positive individuals. (A) Replication kinetics of 
NL4-3/GFP containing a wild-type C-clade p24 compared with three mutants containing an accumulation of polymorphisms in the three epitopes. Infec-
tivity is expressed as the percentage of GFP-positive Jurkat cells over 8 d after infection. The results are from one experiment that was repeated three 
times, and means ± SEM are shown. (B) Correlation of escape mutations in HLA-B*5703 epitopes and viral loads in 42 HLA-B*5703–positive Zambian 
subjects. The median viral load for each group is shown (horizontal bars). (C and D) Plasma viral loads in two chronically infected HLA-B*5703–positive 
individuals, with an increase in viral load coincident with the appearance of A163X in KF11. Open symbols indicate wild-type epitope in the RNA popula-
tion sequence; closed symbols indicate the first detection of a mutation of A163.JEM VOL. 206, April 13, 2009 
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recipient at the time of the recipient’s first positive antibody 
test were collected, as well as two later samples from the re-
cipient. Fig. 5 shows phylogenetic analyses of single genome 
amplification (SGA)–derived Gag p24 sequences from these 
two pairs alongside analyses of the same sequences using the 
Highlighter program from LANL (available at http://www 
.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter 
.html). The donor and recipient nucleotide sequences are 
compared with a master sequence, which in this case is the 
Reversion of HLA-B*5703–associated mutations  
dominates genotypic changes after virus transmission  
to HLA-B*5703–negative recipients
To  better  evaluate  the  relative  role  of  reversion  of  the 
B*5703-associated mutations compared with acquisition of 
new mutations selected by the host HLA alleles, we studied 
the  evolution  of  the  transmitted  virus  from  two  HLA-
B*5703–positive donors to their HLA-B*5703–negative re-
cipients in further detail. Plasma samples from the donor and 
Figure 3.  The effect of HLA-B*5703–restricted CTL responses on viral load in HLA-B*5703–positive individuals. (A–E) Plasma viral loads in five 
acutely infected HLA-B*5703–positive individuals in Zambia. Arrows indicate the time point at which escape was first detected at A146, I147, and T242 in 
the RNA population sequence. Closed symbols are escaped variants; shaded areas indicate the time period after escape. (F) A comparison of the median 
viral load for all time points before escape and for all time points after escape in five individuals from A–E. The symbols match those in A–E. (G) All data 
points from A–E over 18 mo, fitted with a nonlinear regression (line). (H) Plasma viral loads for 23 HLA-B*5703–negative subjects with acute infection, 
sampled every 6 mo, whose virus carried no HLA-B*5703 footprints. Medians are shown.914 EVOLUTION OF HLA-B*5703 HIV-1 ESCAPE MUTATIONS | Crawford et al.
Figure 4.  Longitudinal viral loads after transmission of escape mutants to 11 HLA-B*5703–negative individuals. (A) A decrease in viral load is 
seen in two HLA-B*5703–negative individuals after transmission of virus containing HLA-B*5703–associated mutations, the reversion of which did not 
occur. (B) Plasma viral load in one HLA-B*5703–negative recipient of virus with mutations in all three p24 epitopes targeted by this allele. Sequence data 
show the appearance of wild-type virus at day 412, which had outgrown the variant by day 455, and a concomitant rise in viral load. This reflects the 
only change in p24 in this individual over this time period. A dotted arrow and lowercase residue indicate a mixed population of wild type and variant.  JEM VOL. 206, April 13, 2009 
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11,545 to 13,376 copies/ml, and increased again to 22,415 
copies/ml at 17 mo, after reversion of the A146P and T242N 
mutation. These longitudinal analyses of two HLA-B*5703–
negative recipients, who were both infected by virus contain-
ing HLA-B*5703 escape mutants from their respective donors, 
show that reversion of HLA-B*5703–associated escape mu-
tants dominates the viral sequence changes within Gag p24. 
This suggests that these reversion events may be a contributing 
factor to the subsequent increases in viral load. In addition, the 
lack of polymorphisms in p24 selected by the recipients’ own 
HLA-B alleles contrasts with the early imprinting that HLA-
B*5703 has on the virus, underscoring the strength of HLA-
B*5703–restricted immune responses.
Rapid progression after transmission of HLA-B*5703 escape 
mutants to HLA-matched recipients
Previous studies in relation to HLA-B*27, another HLA allele 
associated with slow progression in HIV infection (18, 19), 
have suggested that transmission of viruses encoding escape 
mutations in the key HLA-B*27 p24 epitope to HLA-B*27–
positive subjects may adversely affect the ability of the recipi-
ent  to  achieve  successful  control  of  viremia  (20).  This 
prompted us to investigate the effect the transmission of a vi-
rus containing HLA-B*5703 Gag escape variants would have 
on disease progression in HLA-matched recipients. We iden-
tified two such transmission pairs in Zambia for which sam-
ples near the time of seroconversion of the recipient were 
available. In one pair, Z80, both partners were HLA-B*5703 
positive, whereas in the other pair, Z48, the donor was HLA-
B*5703 positive and the recipient was B*5801 positive. HLA-
B*5801, like HLA-B*5703, is associated with slow progression 
to AIDS (7, 21), is very similar in its peptide-binding motif to 
HLA-B*5703 (22), differing by only five amino acids in total 
(23), and presents two of the three p24 epitopes presented by 
HLA-B*5703 (i.e., ISW9 and TW10).
Both  HLA-B*5703–positive  donors  transmitted  virus 
containing escape mutations in all three HLA-B*5703 p24 
epitopes: A146P/I147L in ISW9, A163N in KF11, and 
T242N in TW10 (Fig. 6). A polymorphism in the cyclophilin 
A binding loop, V223X, which is associated with T242N 
(12), was also transmitted to both recipients.
PBMCs were not available to establish the HIV-specific 
CTL responses that were made in these subjects. However, 
on  the  basis  of  the  transmitted  viral  sequences,  it  seems 
likely that Z80M (the recipient) did not have the same op-
portunity to generate responses to any of the three HLA-
B*5703–restricted epitopes—ISW9, KF11, or TW10—that 
would have been possible had she been infected with virus 
encoding the nonmutated epitopes, because the mutations 
donor’s sequence on which the tree is rooted. Both donors 
transmitted  virus  containing  the  ISW9  mutations  A146P/
I147L, as well as T242N in TW10.
In the first transmission pair (Fig. 5 A), a heterogeneous 
population of virus in the donor is evident within the neigh-
bor-joining tree, with a maximum of three synonymous and 
two nonsynonymous changes existing between sequences. At 
the time of seroconversion (month 0), the recipient’s sequences 
were all identical in p24, with the exception of one synony-
mous difference between them and the donor’s master se-
quence. At the second time point (15 mo), two nonsynonymous 
changes were dominant in the recipient’s sequences: one was 
the reversion of A146P to consensus, and the other was a 
change from V to A, the consensus amino acid for subtype C 
at Gag residue 215. The significance of the latter reversion is 
unknown, although Gag-215 is located two amino acids up-
stream of the cyclophilin A binding loop, and polymorphisms 
in this loop can compensate for fitness costs resulting from 
HLA-B*5703–associated mutations (12). At 48 mo after trans-
mission, sequences from the recipient contained four more 
nonsynonymous changes, two of which were in TW10. This 
included reversion of T242N. None of the changes were as-
sociated with the recipient’s HLA alleles (HLA-A*3001/
A*3004/B*4501/B*4501/Cw*0602/Cw*16). Overall, of the 
five nonsynonymous changes that were present in more than 
half of the recipient’s sequences at 48 mo, three were rever-
sions of HLA-B*5703–associated mutations. The viral load of 
the recipient was initially low (7,941 and 9,695 copies/ml at 
seroconversion and at 15 mo, respectively), consistent with 
previous findings (15), but at 48 mo, after reversion of both 
HLA-B*5703–associated escape mutations to consensus, the 
viral load rose to 205,498 copies/ml. This illustrative case de-
scribed in detail shows the impact of reversion and supports the 
hypothesis that reversion to a more replication-competent vi-
rus may contribute to the large increase in viral load.
Similarly, in the recipient of the second transmission pair, 
reversions of HLA-B*5703–associated mutations were the only 
nonsynonymous changes occurring over 17 mo (Fig. 5 B). 
Again, a heterogeneous population was seen in the donor, but 
all of these nucleotide differences were synonymous changes. 
The population in the recipient at the time of seroconversion 
was homogeneous in p24, and 5 mo later, the only change in 
8 out of 10 sequences was the reversion of I147L to consensus. 
Two other sequences at this time point were identical to those 
at seroconversion. 17 mo after seroconversion, two more nu-
cleotide changes resulted in changes at the amino acid level, 
and both of them involved reversion of HLA-B*5703–associ-
ated mutations (A146P and T242N). The viral load in this re-
cipient also increased marginally on reversion of I147L, from 
(C) Plasma viral loads in eight HLA-B*5703–negative recipients. Arrows indicate the time point at which reversion to the wild-type epitope was first de-
tected in the population RNA sequence (e.g., N242T indicates the time point at which the virus had fully reverted from N to T at residue 242, as detected 
in the RNA population sequence). Shaded areas indicate the time period after reversion. (D) A comparison of the median viral load for all time points be-
fore reversion and for all time points after reversion in nine HLA-B*5703–negative individuals from B and C, showing an increase overall (P = 0.07 using 
the Wilcoxon matched pairs test). (E) All data points from B and C over 62 mo, fitted with a nonlinear regression (line).
 916 EVOLUTION OF HLA-B*5703 HIV-1 ESCAPE MUTATIONS | Crawford et al.
Figure 5.  Reversion of Gag p24 HLA-B*5703–associated mutations dominates early infection in HLA-B*5703–negative recipients.  
(A and B) Neighbor-joining trees of SGA-derived p24 sequences (231 amino acids) from (A) transmission pair 1 and (B) transmission pair 2. Both donors are 
HLA-B*5703 positive, and both recipients are HLA-B*5703–negative. Trees are rooted to the first donor sequence. (A) Donor 1 transmitted a virus containing 
polymorphisms in all three Gag p24 B*57 epitopes: A146P/I147L, A163N, and T242N. Clones from recipient 1 from time points A (day of seroconversion), JEM VOL. 206, April 13, 2009 
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HIV-1 C clade–infected populations. Both HLA-B*5703–
positive donors and their HLA-matched and -mismatched 
transmission recipients were analyzed. Broad CTL responses 
that target epitopes in Gag p24 are associated with decreased 
viral  loads  (7,  27),  and  HLA-B*5703  CTLs  target  three 
peptides in this conserved region. We show that the escape 
polymorphisms are selected in similar frequencies in these 
p24 epitopes in HLA-B*5703–positive individuals in both 
Zambia and South Africa, where this HLA allele is associ-
ated with lower viral loads (2, 21). We also noted that the 
order of HIV escape in C clade differed from that in HIV-1 
B clade–infected individuals with the B*5701 allele, sug-
gesting that mutational pathways may be B*57 allele or 
clade specific. Although sequential addition of the observed 
HLA-B*5703–associated mutations in the three Gag p24 
epitopes results in an incremental reduction in viral fitness 
in vitro, changes in all three epitopes are found in the   
majority (64%; 54 out of 84) of chronically infected HLA-
B*5703–positive individuals. Indeed, higher viral loads were 
observed in HLA-B*5703–positive individuals with muta-
tions in all three Gag p24 epitopes in the absence of any 
consistent compensatory mutations. This does not reflect 
the malleability of p24, because it is a highly conserved 
region (28), but rather the highly effective nature of HLA-
B*5703–restricted  immune  responses  in  selecting  escape 
mutations. Despite the lack of actual CTL data, this strong 
pressure is evident in the early appearance of escape muta-
tions (ISW9 mutations were observed in all B*5703 in-
dividuals  at  the  seroconversion  time  point,  and  TW10 
mutations were first detected here at 4–18 mo after sero-
conversion; median = 13 mo) compared with the relatively 
slower reversion rate (7–55 mo; median = 23 mo), as well 
as a 10-fold lower median viral load in acute infection in 
HLA-B*5703–positive compared with HLA-B*5703–neg-
ative  individuals.  This  is  an  observation  consistent  with 
other studies showing that, first, HLA-B*57–restricted CTL 
responses are effective and large in magnitude (5, 29), and 
second,  that  compensatory  mutations  are  sometimes  se-
lected to help minimize this cost (12). Thus, these studies 
suggest that although the fitness costs associated with HLA-
B*5703–driven Gag escape mutations may contribute to 
successful containment of HIV in HLA-B*5703–positive 
subjects, durable control of viremia depends also on the 
maintenance of effective CTL responses.
These data are therefore consistent with recent SIV stud-
ies in the Burmese macaque model showing, first, that multi-
ple Gag-specific CTL responses can be responsible for control 
of viral replication but that the accumulation of CTL muta-
tions in each of the epitopes can result in viral evasion from 
this control (30), and second, that although the sequential 
observed in the ISW9 and KF11 epitopes affect peptide 
processing and epitope presentation (24, 25). The presence 
of an additional mutation, A248T, in the Z80M sequence 
subsequent to transmission within the TW10 epitope may 
suggest that either a CTL response was generated to the 
transmitted T242N mutant epitope, as has been previously 
described in HLA-B*5703/B*5801–positive infants born to 
infected mothers (26), or that this represents selection of a 
compensatory mutation to T242N, as previously described 
(12). It is notable that within 11 mo of seroconversion, this 
recipient’s viral load had reached a level similar to the me-
dian viral load of the chronically infected HLA-B*5703–
positive  individuals  with  mutations  in  all  three  epitopes 
(Fig. 3 B). This suggests that the HLA-B*5703 allele was 
doing little to protect against a relatively rapid increase in 
viral load. It is uncertain whether these events are causally 
linked  to  clinical  outcome,  as  this  individual  died  from 
chronic gastroenteritis <14 mo after seroconversion (CD4 
cell counts are unavailable).
An unexpectedly rapid disease course for an individual 
expressing the HLA-B*5801 allele was also observed in the 
recipient Z48F (Fig. 6 B). Viral set point at 4 mo after trans-
mission was extremely high at 153,451 copies/ml. As in re-
cipient Z80M, this HLA-B*5801–positive recipient received 
a virus with the ISW9 and TW10 epitopes mutated, and it is 
therefore probable that optimal responses to wild-type ISW9 
and TW10 epitopes could not have been generated. The re-
version of A146P to consensus in this recipient’s virus sup-
ports  the  prediction  that  no  ISW9-specific  response  was 
made. The combined observations at 17 mo after transmis-
sion of the compensatory mutation H219Q (11, 12), rever-
sion of A146P, and an increase in viral load (from 153,451 to 
613,919 copies/ml in just 13 mo) are consistent with an in-
creased viral replicative capacity. This rapid increase in viral 
load would not normally be associated with an individual 
carrying HLA-B*5801 (2) at only 17 mo after infection.
Collectively, the final viral loads for these two individuals 
are substantially higher than the viral loads observed in five 
HLA-B*5703–positive individuals (Fig. 3, A–E) measured at a 
similar time after infection who did not receive escape variants 
(<400–17,351 copies/ml; median = 2,131 copies/ml). Thus, 
the unfavorable outcomes in the two recipients (Z80F and 
Z48M) appear to be linked, albeit anecdotally, to the inacces-
sibility of p24 CTL epitopes on which the association with 
immune control of HIV infection may be likely to hinge (8).
DISCUSSION
In  this  paper,  we  have  investigated  the  role  of  HLA-
B*5703–restricted Gag CTL responses and the consequent 
mutations selected to evade these responses in two distinct 
B (15 mo), and C (48 mo) are shown. The Highlighter analysis, in which green indicates a synonymous nucleotide change and red indicates a nonsynony-
mous change, shows that the predominant amino acid changes in the recipient sequences are reversions of B*5703–associated polymorphisms. Epitopes 
ISW9 and TW10 are boxed. (B) Similarly, donor 2 transmitted a virus containing A146P, I147L, and T242N. Clones from recipient 2 from time points A (day 
of seroconversion), B (5 mo), and C (17 mo) show that reversions of A146P, I147L, and T242N are the only nonsynonymous changes in Gag p24.
 918 EVOLUTION OF HLA-B*5703 HIV-1 ESCAPE MUTATIONS | Crawford et al.
HLA-B*5703–negative recipients contrasts with the changes 
in p24 selected by HLA-B*5703 CTL responses dominating 
early infection in HLA-B*5703–positive individuals. Although 
early viremia may be influenced significantly by the escape 
mutations transmitted (9, 15), the findings presented in this 
paper suggest that long-term control of viremia ultimately 
rests more on the host’s own HLA class I alleles and the 
CTLs generated.
The importance of HLA-B*5703–restricted CTLs is again 
suggested  by  the  observation  of  rapid  progression  in  two 
HLA-B*57/5801–positive recipients of virus containing 
HLA-B*5703–associated mutations in Gag (death at 14 mo 
after transmission in one case, and a viral load of >600,000 
copies/ml by 17 mo after transmission in the second). Previ-
ous mother-to-child transmission studies involving HLA-
B*27–positive infants support the hypothesis that transmission 
of viruses encoding escape mutations in the key Gag epitopes 
can dislocate the association between a protective MHC class 
I allele and control of immunodeficiency virus infection (20). 
A recent study of Mamu-A*90120-1a–positive Burmese ma-
caques addresses this issue more directly (33). These macaques 
were previously vaccinated with a DNA prime/Gag-express-
ing Sendai virus vector boost and contained viral replication 
after a SIVmac239 challenge (34). However, when the vacci-
nated macaques were infected with virus containing multiple 
Gag CTL mutations that had been selected in other Mamu-
A*90120-1a–positive macaques, they generated small or no 
CTL responses to these epitopes, and failed to control viral 
replication despite the variants having a lower replicative abil-
ity compared with the wild type (33). This emphasizes the 
central role of Gag-specific CTL responses in the early con-
tainment of viral replication and suggests that the benefit as-
sociated with certain HLA alleles may be lost in individuals 
who are infected by virus from HLA-matched donors.
These results initially appear to be in contrast with a re-
cent case study of a single HLA-B*5703–matched transmis-
sion pair (35) that reported sustained, excellent virological 
control in the recipient despite the apparent transmission of 
addition of escape mutations substantially reduced in vitro 
viral fitness, those same viruses encoding multiple Gag muta-
tions could still replicate to high levels and result in progres-
sion in vivo (31).
Nevertheless, despite the high viral loads seen in chroni-
cally infected HLA-B*5703–positive individuals, the median 
viral load of this subgroup of the population (67,000 cop-
ies/ml) remains lower than that seen in the rest of the popula-
tion  (110,000  copies/ml),  showing  that  carriage  of  this 
HLA allele is beneficial despite the frequent selection of es-
cape mutations and evasion of the cellular immune response. 
In addition, because of high reversion rates, HLA-B*5703 
epitopes are likely to persist throughout the epidemic, pro-
viding stable targets for individuals with this allele.
The second aspect of the data presented in this paper ad-
dressed the impact of HLA-B*5703–associated mutations 
on  disease  outcome  in  HLA-matched  and  -mismatched 
transmission recipients. Two recent studies reported lower 
viral set points in HLA-B*5703–negative recipients who 
were infected by virus with two or more HLA-B*5703–as-
sociated mutations (9, 15). Our data suggest that this benefit 
may only be transient in HLA-B*5703–negative recipients, 
because reversion of HLA-B*5703–associated mutations 
coincides with an overall increase in median viral load. Al-
though viral load might be expected to increase in the natu-
ral disease course in these HIV-infected individuals, studied 
for between 16 and 62 mo, this observation contrasts with 
the lack of change in viral load coincident with epitope es-
cape and CTL responses in the HLA-B*5703–positive indi-
viduals, studied for a similar length of time (11–58 mo), and 
a stable viral set point seen in a control group under no in-
fluence of HLA-B*5703. Detailed analysis of two HLA-
B*5703–negative recipients revealed the extent to which 
reversion of these mutations dominates the genotypic changes 
in early infection. These data are consistent with previously 
published  findings  in  other  HLA  types  that  reversion  is 
prevalent in early infection (32). The observation that re-
version is the main driving force of p24 evolution in these 
Figure 6.  Transmission of virus containing HLA-B*5703–associated mutations from an HLA-B*5703–positive donor to HLA-B*5703– or 
HLA-B*5801–positive recipients. (A and B) Gag p24 sequences (residues 145–253) from (A) an HLA-B*5703–positive female donor (Z80F) aligned with 
sequences from the HLA-B*5703–positive male recipient, and (B) an HLA-B*5703–positive male donor (Z48M) aligned with sequences from the HLA-
B*5801–positive female recipient. HLA-B*5703 epitopes are highlighted, and the cyclophilin A binding loop is boxed. Viral loads are indicated. Ab, anti–
HIV-1 antibody; Pop., population RNA sequences; SGA seq., sequences derived from SGA from viral RNA.JEM VOL. 206, April 13, 2009 
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Site-directed  mutagenesis.  The  plasmid  p83-2  encoding  the  5  ge-
nomic half of HIV-1 strain NL4-3 (41), substituted with the p24 capsid 
coding region from a C clade–infected child (13), was modified using the 
QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies). This 
p24 region encoded the mutations A146P, I147L, and S252N. First, the 
ISW9 (A146P/I147L) mutant virus was constructed by reverting S252N 
using  5-GCATGGATGACAAGTAATCCACCTATCCCAGTAGG-3  
(HXB2 nt 5,044). The wild-type virus was then constructed by revert-
ing  A146P  and  I147L  using  5-GGGGCAAATGGTACATCAGGCC-
ATATCACCTAGAAC-3  (nt  1,225  and  1,228).  The  ISW9/TW10 
mutant virus was constructed by introducing T242N to the ISW9 mutant 
using  5-GTGACATAGCAGGAACTACTAGTAACCTTCAGGAAC-3  
(nt 5,014), and A163G and S165N were introduced to this plasmid to 
construct  the  ISW9/TW10/KF11  mutant  using  5-AGTAGAAGAGA-
AGGGTTTCAACCAGAAGTA-3 (nt 1,277 and 1,283). Mutagenesis sites 
are underlined. The mutants were verified by sequencing after each step, 
and were subcloned into new p83-2 plasmids using the unique restriction 
sites SapI (nt 1,098) and ApaI (nt 2,005) to avoid carryover of any unwanted 
mutations in the mutagenized plasmid. The p24 coding region sequences for 
each mutant were verified before the generation of viral stocks.
Generation of infectious viral stocks. Viral stocks were generated in 
Jurkat cells using previously published methods (13). In brief, the plasmid 
carrying the 5 half of the genome (p83-2 and constructed mutants) and 
plasmid p83-10 (41), carrying the 3 half of the genome of HIV-1 NL4-3 
(which also encoded the GFP in frame with Nef), were linearized using Eco 
RI and electroporated into Jurkat cells. Cells were grown for 7 d, at which 
time the supernatants were collected. The 50% tissue culture infective dose 
was determined for each viral stock using the Spearman-Karber method.
Viral replication assays. 7.5 × 106 Jurkat cells were infected at a multiplic-
ity of infection of 0.01, incubated at 37°C for 2 h, washed twice, and resus-
pended in 15 ml R10 (RPMI 1640 [Sigma-Aldrich], 10% fetal calf serum, 
10% l-glutamate, and 10% penicillin/streptomycin). Cultures were divided 
into 3 wells of 2.5 × 106 cells each and incubated at 37°C. 200 µl of culture 
was collected every day for 8 d, and the cells were fixed in 2% formaldehyde. 
The percentage of GFP-expressing cells was measured by FACS analysis using 
a flow cytometer (FACSCalibur; BD) and analyzed using FlowJo software 
(version 8.6.3; Tree Star, Inc.). Experiments were performed in triplicate.
Statistical analysis. The analysis of polymorphisms associated with HLA-
B*5703 was undertaken using Fisher’s exact test (Fig. 1, A and B). The Wil-
coxon matched pairs test was used to compare the two paired groups in Figs. 3 
F and 4 D. Median plasma viral loads in Fig. 2 B were analyzed using the 
Mann-Whitney U test, and nonlinear regressions were fitted in Figs. 3   
G and 4 E. All statistical analyses were undertaken using Prism (version 5.0; 
GraphPad Software, Inc.).
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an HLA-B*5703 escape mutant. However, in this case, the 
recipient also carried the HLA-B*27 allele and mounted a 
large CTL response toward the p24 epitope KK10, which is 
associated with long-term control of viremia (19). Further-
more, the HLA-B*5703–associated mutations may have been 
selected by the recipient’s own potent CTL responses early in 
infection, as the sequences were obtained at least 5 yr after 
the likely transmission event.
In summary, these analyses of the evolution and trans-
mission of HLA-B*5703–associated CTL mutations under-
line the importance of CTL responses in the control of HIV 
replication in both HLA-B*5703–positive and –negative in-
dividuals. The presence of escape mutations that reduce viral 
replicative capacity is not sufficient to provide long-term 
protection against HIV disease progression in HLA-B*5703–
positive individuals, because the virus can still replicate to 
high levels in the absence of functional CTLs. In HLA-mis-
matched recipients, the reversion of these escape mutants, 
together with increases in viremia, suggest a limited long-
term benefit of these mutations unless these individuals, too, 
can generate effective CTLs against the virus. Further, the 
unfavorable outcome in HLA-matched recipients of virus 
escaped in all three HLA-B*5703 p24 epitopes is likely 
linked to their inability to mount effective CTL responses 
against these key epitopes. Therefore, although mutations 
that affect fitness can assist in decreasing viral replicative ca-
pacity, in the absence of continued CTL pressure, it is likely 
that disease progression will occur. Thus, for an HIV vaccine 
to be truly effective in the long term as opposed to the short 
term, it will need to stimulate broad CTL responses against 
multiple epitopes that will continue to control viremia in the 
face of sequential escape.
MATERIALS AND METHODS
Study cohorts. The South African cohort consisted of 645 HIV C clade–
infected patients recruited from clinics in Durban, South Africa (2, 7). The 
178 HIV-1 C clade chronically infected Zambian subjects were selected 
from the Zambia-Emory HIV Research Project cohort of HIV-1 serodis-
cordant  cohabiting  heterosexual  couples.  This  cohort  was  established  in 
1994 in Lusaka, Zambia to provide voluntary HIV testing, counseling, health 
care, and follow up (36). HIV-negative partners are monitored for antibody 
seroconversion at 3-mo intervals, and epidemiological linkage of the viruses 
in subsequent HIV-1 transmission pairs (8.5% of couples per year) is con-
firmed by phylogenetic analyses of env sequences (37). Plasma viral loads for 
all subjects were determined using the Amplicor HIV-1 Monitor Test (ver-
sion 1.5; Roche). HLA class I typing was performed as previously described 
(38, 39). The patients in both cohorts were antiretroviral therapy naive, and 
all gave written informed consent. All research protocols were approved by 
the ethics committees in Durban, South Africa and Lusaka, Zambia, and by 
the Oxford University and Emory University Institutional Review Boards.
Isolation, amplification, and sequencing of HIV-1 proviral DNA 
and viral RNA. Genomic DNA from South African samples was extracted 
from PBMCs, amplified, and sequenced, as previously described (11). Viral 
RNA from Zambian samples was extracted using a robotic system with the 
MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche). Amplification 
and population sequencing of Gag was performed as previously described 
(15); for SGA and sequencing, we used previously described methods (40), 
but with the gag-specific primers from the population sequencing (15). Se-
quences were analyzed using Sequencher 4.8 (Gene Codes Corp.)920 EVOLUTION OF HLA-B*5703 HIV-1 ESCAPE MUTATIONS | Crawford et al.
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